AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- RAD's CEO and MD Riccardo Canevari has commented the partnership would "improve access to innovative therapies"
- Three Phase 1 clinical trials involving RAD's radiopharmaceutical molecules would be conducted by GenesisCare
- The trials would take place in Australia where regulatory landscape promotes R&D in theranostics and precision medicine
Australia's Radiopharm Theranostics (ASX: RAD) -- developing radiopharmaceutical products meant for diagnostic and therapeutic uses -- has announced a two-year collaboration with GenesisCare. GenesisCare, a cancer care and theranostics research centre, and RAD would progress on Phase 1 clinical trials under this partnership, with the former's Contract Research Organisation and Imaging Research Organisation undertaking trials of RAD's platform of radiopharmaceutical technologies in Australia.
Source: RAD ASX announcement dated 27 March 2023
The development
Radiopharm Theranostics has come together with a leading global cancer care and theranostics research provider GenesisCare to undertake collaborative strategic research in the field of novel radiopharmaceuticals. This partnership would see the two companies working in the areas of unmet needs in the oncology domain. GenesisCare will be conducting Phase 1 clinical trials to determine safety and tolerability of novel radiopharmaceuticals.
Two arms of GenesisCare -- Contract Research Organisation, and Imaging Research Organisation -- would be involved in the trials that are to be done in Australia. Radiopharm has further said that radiopharmaceutical therapies work to deliver small amounts of radiation. The purpose is to specifically target cells for therapeutic or diagnostic uses. It is also stated that tumour-specific targets, which are not found in the body's healthy tissue, are needed to develop effective radiopharmaceuticals.
Metastatic prostate cancer and neuroendocrine tumours are the two ailments that so far have been aimed by majority of clinical developments in the field. The clinical trials (Phase 1) by GenesisCare would involve the following.
- RAD's proprietary nanobody from Radiopharm’s own Nano-mAbs platform (targets PDL1 expression in non-small cell lung cancer)
- RAD's PTPu targeting peptide (for application in Brain Tumors)
- RAD's PSA targeting antibody (targets free human prostate kallikrein in prostate cancer cells)
Statements
RAD's CEO and Managing Director Riccardo Canevari has lauded the partnership with GenesisCare and asserted that this development would enable improved access to "innovative therapies" for people on a global scale. Dr Danielle Meyrick -- Chief Scientific Officer, Research & Insights of GenesisCare -- has also praised the "exciting pipeline of research" to be undertaken in the country and the coming together of two Australian-founded healthcare entities.
About Radiopharm
The ASX-listed clinical stage radiotherapeutics company is developing products in the field of unmet medical needs. It has a pipeline of six “highly differentiated platform technologies” for applications in cancer treatment. These technologies are in pre-clinical and clinical stages at some of the prominent universities and institutes of the world. The program includes a Phase 2 trial, along with three Phase 1 trial targeting breast, kidney, and brain cancers.
RAD's ASX-listed shares traded at AU$0.17 at the time of writing on 28 March 2023.
